Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Leqembi Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Leqembi iqlik Prior Authorization and Quantity Limits

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Commercial coverage, prior authorization, and quantity-limit exceptions for Leqembi iqlik autoinjector pens used to treat Alzheimer's disease in Boeing commercial members.

    Policy Summary
    PayerPrime Therapeutics
    PolicyLeqembi iqlik Prior Authorization and Quantity Limits
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing at least 18 months of prior Leqembi IV treatment before requesting initial Leqembi iqlik approval.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial and renewal approval duration
    18 monthsPrior Leqembi IV treatment before initial approval
    28 daysQuantity-limit program day supply
    2 strengthsAvailable iqlik strengths

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    MRI monitoring
    Required MRI monitoring

    Coverage Criteria

    Initial Therapy

    Covered for initial therapy when ALL of the following are met. Length of approval: 12 months. If a quantity limit applies, refer to the Quantity Limit Criteria.

    ALL of the following

    • The patient has a diagnosis of Alzheimer's disease.
    • The patient is being treated with the requested agent for mild cognitive impairment or mild dementia.
    • ONE of the following

      • If the requested agent has an FDA-labeled indication, the patient's age is within FDA labeling for the requested indication.
      • There is support for using the requested agent for the patient's age and requested indication.
    • The patient has received at least 18 months of treatment with the Leqembi IV formulation.
    • The patient has had clinical benefit and/or no worsening of disease.
    • The patient has had an absence of unacceptable toxicity to the Leqembi IV doses.
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist, gerontologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • The patient does NOT have any FDA-labeled contraindications to the requested agent.

    Renewal Therapy

    Target agent(s) will be approved for renewal when ALL of the following are met. Length of approval: 12 months. If a quantity limit applies, refer to the Quantity Limit Criteria.

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's Prior Authorization process.

      Patients not previously approved for the requested agent require initial evaluation review.

    • The patient does NOT have any evidence of unacceptable toxicity from the drug, including amyloid-related imaging abnormalities-edema (ARIA-E), amyloid-related imaging abnormalities-hemosiderin deposition (ARIA-H), intracerebral hemorrhage, or hypersensitivity reactions including angioedema, bronchospasm, and anaphylaxis, or infusion-related reactions.
    • The patient has responded to therapy compared to pretreatment baseline, as evidenced by improvement, stability, or slowing in cognitive and/or functional impairment in at least one cognitive function test (e.g., Alzheimer's Disease Assessment Scale-Cognitive [ADAS-Cog 13/14], Activities of Daily Living for Mild Cognitive Impairment [ADCS-ADL-MCI] scale, Mini Mental State Examination [MMSE], Clinical Dementia Rating Sum of Boxes [CDR-SB], or Montreal Cognitive Assessment [MoCA]).

    Coverage requires that the requested agent NOT be used in combination with another anti-amyloid immunotherapy, including donanemab or lecanemab IV. An exception applies during switch therapy with lecanemab IV.

    Prior Authorization and Provider Requirements

    Prior Authorization

    Initial Prior Authorization Requirements

    Prior authorization is required for initial approval. Approve when the patient is being treated for mild cognitive impairment or mild dementia, has received at least 18 months of Leqembi IV treatment, has clinical benefit and/or no worsening of disease, and has no unacceptable toxicity. The prescriber must be a specialist in the diagnosis area or have consulted with one; the patient must not use the agent with another anti-amyloid immunotherapy (except during switch therapy with lecanemab IV) and must have no FDA-labeled contraindication.

    • If the requested agent has an FDA-labeled indication, the patient's age must be within the labeling or there must be support for use at the patient's age for the requested indication.
    • Initial approval length: 12 months.
    • If a quantity limit applies, also apply the Quantity Limit Criteria.
    Prior Authorization

    Renewal Prior Authorization Requirements

    Renewal approval requires all renewal conditions to be met. The patient must have been previously approved through the plan's prior authorization process, have no unacceptable toxicity, demonstrate response compared with pretreatment baseline, remain without progression to moderate or severe Alzheimer's disease, and satisfy required MRI monitoring and ARIA management requirements.

    Clinical Background

    Leqembi iqlik is the subcutaneous autoinjector formulation of lecanemab-irmb addressed by this policy. Coverage applies to patients with Alzheimer's disease who are being treated for mild cognitive impairment or mild dementia. Initial approval requires at least 18 months of prior treatment with the Leqembi IV formulation, while continued coverage depends on clinical benefit or stability, absence of progression to moderate or severe Alzheimer's disease, and monitoring for amyloid-related imaging abnormalities and other toxicity.

    Clinical and Radiographic Definitions

    Mildly symptomatic
    DefinitionDiscomfort noticed, but with no disruption of normal daily activity.
    Moderate symptoms
    DefinitionDiscomfort sufficient to reduce or affect normal daily activity.
    Severe symptoms
    DefinitionIncapacitating, with inability to work or perform normal daily activity.
    Mild radiographic ARIA-E severity
    MRI finding

    Leqembi iqlik Initial Therapy

    Leqembi iqlik Initial Therapy

    Initial approval requires ALL of the following criteria.

    Initial Leqembi iqlik therapy

    • Clinical requirements: The patient has Alzheimer's disease; is being treated for mild cognitive impairment or mild dementia; and, when an FDA-labeled indication applies, is within the FDA-labeled age range or there is support for use at the patient's age for the requested indication.
    • Prior Leqembi IV treatment: The patient has received at least 18 months of treatment with the Leqembi IV formulation.>=18 months
    • Response and safety: The patient has had clinical benefit and/or no worsening of disease and has had no unacceptable toxicity from Leqembi IV doses.

    Leqembi iqlik Continuation

    Leqembi iqlik Continuation

    Renewal approval requires ALL of the following criteria.

    Leqembi iqlik continuation

    • Prior approval and safety: The patient was previously approved for the requested agent through the plan's prior authorization process and has no unacceptable drug toxicity, including ARIA-E, ARIA-H, intracerebral hemorrhage, hypersensitivity reactions, or infusion-related reactions.
    • Treatment response and disease stage: Compared with pretreatment baseline, the patient has improvement, stability, or slowing of cognitive and/or functional impairment in at least one cognitive function test, and does not have evidence of progression to moderate or severe Alzheimer's disease.At least 1 cognitive function test

      Examples include ADAS-Cog, ADCS-ADL-MCI, MMSE, CDR-SB, and MoCA.

    Required Prior Therapy

    StepTherapy requirementPrior treatment duration
    1Before initial approval of Leqembi iqlik, the patient must have received treatment with the Leqembi IV formulation.At least 18 months

    Quantity Limits and Available Strengths

    Leqembi iqlik quantity limit
    ProductLeqembi iqlik (lecanemab-irmb solution autoinjector).
    Dosage formPens.
    Available strengths250 mg/1.25 mL and 360 mg/1.8 mL.
    Quantity limit28 days.
    Policy Summary
    PayerPrime Therapeutics
    PolicyLeqembi iqlik Prior Authorization and Quantity Limits
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation showing at least 18 months of prior Leqembi IV treatment before requesting initial Leqembi iqlik approval.
    SourceLink
    On This Page
    Coverage CriteriaPrior Authorization and Provider RequirementsClinical BackgroundClinical and Radiographic DefinitionsLeqembi iqlik Initial TherapyLeqembi iqlik ContinuationRequired Prior TherapyQuantity Limits and Available Strengths
    The patient does NOT have evidence of progressing to moderate or severe Alzheimer's disease.
  1. The patient has received a pre-3rd, 5th, 7th, AND 14th infusion MRI for monitoring of amyloid-related imaging abnormalities-edema (ARIA-E) and amyloid-related imaging abnormalities-hemosiderin deposition (ARIA-H) microhemorrhages.
  2. If the patient has evidence of ARIA-E abnormalities, ONE of the following

    • The patient is asymptomatic or mildly symptomatic (discomfort noticed, but no disruption of normal daily activity) with mild radiographic severity on MRI, defined as FLAIR hyperintensity confined to the sulcus and/or cortex/subcortex white matter in one location measuring less than 5 cm.
    • The patient is asymptomatic or mildly symptomatic with moderate to severe radiographic severity on MRI, and administration will be suspended until MRI demonstrates radiographic stabilization and symptoms, if present, resolve.

      Moderate radiographic severity is defined as FLAIR hyperintensity measuring 5 to 10 cm in single greatest dimension, or more than 1 site of involvement, each measuring less than 10 cm. Severe radiographic severity is defined as FLAIR hyperintensity measuring greater than 10 cm with associated gyral swelling and sulcal effacement, or one or more separate/independent sites of focal areas of superficial siderosis.

    • The patient is symptomatic with mild to moderate radiographic severity on MRI, and administration will be suspended until MRI demonstrates radiographic stabilization and symptoms, if present, resolve.
    • The patient has moderate to severe symptoms (moderate symptoms are defined as discomfort sufficient to reduce or affect normal daily activity; severe symptoms are defined as incapacitating, with inability to work or perform normal daily activity) with mild to severe radiographic severity on MRI, and administration will be suspended until MRI demonstrates radiographic stabilization and symptoms, if present, resolve.
    • The patient has severe radiographic severity on MRI, defined as 10 or more new incident microhemorrhages or greater than 2 focal areas of superficial siderosis, and administration will be suspended until MRI demonstrates radiographic stabilization and symptoms, if present, resolve.
    • There is support that continued use of the requested agent is clinically appropriate for the patient.
  3. The prescriber is a specialist in the area of the patient's diagnosis (e.g., neurologist, gerontologist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
  4. The patient does NOT have any FDA-labeled contraindications to the requested agent.
    • Response may be shown by improvement, stability, or slowing of cognitive and/or functional impairment on at least one cognitive or functional assessment, such as ADAS-Cog, ADCS-ADL-MCI, MMSE, CDR-SB, or MoCA.
    • Required monitoring includes MRI before the 3rd, 5th, 7th, and 14th infusions for ARIA-E and ARIA-H microhemorrhages.
    • If ARIA is present, administration must be suspended when required until MRI demonstrates radiographic stabilization and any symptoms resolve; continued treatment must otherwise be clinically appropriate.
    • The prescriber must be a specialist or have consulted with a specialist, the patient must not use another anti-amyloid immunotherapy except during switch therapy with lecanemab IV, and no FDA-labeled contraindication may be present.
    • Renewal approval length: 12 months.
    Documentation Required

    Initial Request Documentation

    Document the initial request before review. Submit records establishing the diagnosis and treatment stage, prior Leqembi IV use, and clinical benefit or absence of disease worsening. Include relevant prescriber and treatment information needed to evaluate the initial criteria.

    • Diagnosis of mild cognitive impairment or mild dementia.
    • At least 18 months of treatment with the Leqembi IV formulation.
    • Clinical benefit and/or no worsening of disease.
    • Prescriber specialty or evidence of consultation with a specialist in the diagnosis area, when needed to support the request.
    Documentation Required

    Renewal Documentation

    Submit renewal records that support continued treatment. Documentation should include assessment results compared with pretreatment baseline, current disease stage, treatment response, toxicity and ARIA status, MRI monitoring results, and the treatment plan when administration has been suspended.

    • Cognitive or functional assessment results showing improvement, stability, or slowing of impairment.
    • Records supporting that the patient has not progressed to moderate or severe Alzheimer's disease.
    • MRI reports from monitoring before the 3rd, 5th, 7th, and 14th infusions, including ARIA-E and ARIA-H findings.
    • Documentation of any ARIA symptoms and radiographic severity, treatment suspension, radiographic stabilization, symptom resolution, and clinical rationale for continuation when applicable.
    • Records confirming specialist prescribing or consultation, absence of prohibited combination therapy, and absence of FDA-labeled contraindications.
    Documentation Required

    Quantity-Limit Exception Documentation

    When the requested quantity exceeds the program limit, document the dose and the exception rationale. The request must identify the requested quantity or dose, the FDA-labeled maximum dose for the indication when one exists, and clinical support for the higher quantity or dose.

    • State whether the requested quantity exceeds the program quantity limit.
    • If there is no FDA-labeled maximum dose, provide support for therapy at the higher dose.
    • If the requested quantity does not exceed the FDA-labeled maximum, explain why it cannot be achieved with a lower quantity of a higher strength that remains within the program quantity limit.
    • If the requested quantity exceeds the FDA-labeled maximum, provide support for therapy with the higher dose for the requested indication.
    Denial Risk

    Initial Criteria Not Met

    Initial criteria are not met when required treatment, benefit, safety, or prescriber conditions cannot be established. An initial request should be denied when the patient does not have mild cognitive impairment or mild dementia, has not received at least 18 months of Leqembi IV treatment, lacks clinical benefit or has worsening disease, or has unacceptable toxicity.

    • The patient's age is outside FDA labeling without supporting evidence for use at that age, when an FDA-labeled indication applies.
    • The prescriber is neither a relevant specialist nor supported by specialist consultation.
    • The patient will use the requested agent with another anti-amyloid immunotherapy, other than during switch therapy with lecanemab IV.
    • An FDA-labeled contraindication is present.
    Denial Risk

    Renewal Criteria Not Met

    Renewal should be denied when continued-treatment requirements are not satisfied. Denial conditions include lack of prior plan approval, unacceptable toxicity, lack of treatment response, progression to moderate or severe Alzheimer's disease, inadequate MRI monitoring, or ARIA findings without the required management and clinical support.

    • The patient has unacceptable toxicity, including ARIA-E, ARIA-H or intracerebral hemorrhage, hypersensitivity reactions such as angioedema, bronchospasm, or anaphylaxis, or infusion-related reactions.
    • The patient has not demonstrated improvement, stability, or slowing of cognitive or functional impairment compared with pretreatment baseline.
    • The patient has progressed to moderate or severe Alzheimer's disease.
    • Required MRI monitoring before the 3rd, 5th, 7th, and 14th infusions is absent or does not support continued treatment.
    • ARIA findings do not meet the permitted clinical and radiographic conditions, treatment is not suspended when required, stabilization or symptom resolution is not documented, or continued use is not clinically appropriate.
    • The prescriber lacks specialist involvement, prohibited combination therapy is planned, or an FDA-labeled contraindication is present.
    Denial Risk

    Quantity-Limit Exception Unsupported

    A quantity-limit exception is not supported when the request lacks the required dose or clinical rationale. Deny the exception when the requested quantity or dose, applicable FDA-labeled maximum, or support for the higher quantity is not adequately documented.

    • The requested quantity exceeds the program limit without support for therapy at the higher dose.
    • For an agent without a maximum FDA-labeled dose, support for the higher dose is absent.
    • The requested quantity is within the FDA-labeled maximum, but the request does not explain why a lower quantity of a higher strength within the program limit cannot be used.
    • The requested quantity exceeds the FDA-labeled maximum and the request lacks support for therapy with the higher dose for the indication.
    FLAIR hyperintensity confined to the sulcus and/or cortex/subcortex white matter in one location measuring less than 5 cm.
    Moderate radiographic ARIA-E severity
    MRI findingFLAIR hyperintensity measuring 5 to 10 cm in the single greatest dimension, or more than one site of involvement with each site measuring less than 10 cm.
    Severe radiographic ARIA severity
    Severe ARIA-EFLAIR hyperintensity greater than 10 cm with associated gyral swelling and sulcal effacement.
    Severe ARIA-H10 or more new incident microhemorrhages or greater than 2 focal areas of superficial siderosis.
  5. Prescriber and concomitant therapy: The prescriber is a specialist in the area of the patient's diagnosis or has consulted with one; the requested agent will not be used in combination with another anti-amyloid immunotherapy, except during switch therapy with lecanemab IV; and the patient does not have an FDA-labeled contraindication to the requested agent.
  6. MRI monitoring:
    The patient has received MRI monitoring before the 3rd, 5th, 7th, and 14th infusions for ARIA-E and ARIA-H microhemorrhages.
    Pre-3rd, 5th, 7th, and 14th infusion MRI
  7. ARIA management

    • Asymptomatic or mildly symptomatic with mild radiographic severity: The patient is asymptomatic or mildly symptomatic and has mild radiographic severity.
    • Asymptomatic or mildly symptomatic with moderate to severe radiographic severity: The patient is asymptomatic or mildly symptomatic with moderate to severe radiographic severity, and administration is suspended until MRI stabilization and symptom resolution when applicable.
    • Symptomatic with mild to moderate radiographic severity: The patient is symptomatic with mild to moderate radiographic severity, and administration is suspended until MRI stabilization and symptom resolution when applicable.
    • Severe radiographic severity: The patient has severe radiographic severity, and administration is suspended until MRI stabilization and symptom resolution when applicable.10 or more new incident microhemorrhages or >2 focal areas of superficial siderosis
    • Clinical appropriateness: There is support that continued use of the requested agent is clinically appropriate for the patient.
  8. Prescriber and concomitant therapy: The prescriber is a specialist in the area of the patient's diagnosis or has consulted with one; the requested agent will not be used in combination with another anti-amyloid immunotherapy, except during switch therapy with lecanemab IV; and the patient does not have an FDA-labeled contraindication to the requested agent.